Na+/I- симпортер (NIS): структура, функции, экспрессия в норме и опухолях

Автор: Джикия Е.Л., Авилов О.Н., Киселева Я.Ю., Кулинич Т.М., Боженко В.К.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Статья в выпуске: 1 т.18, 2018 года.

Бесплатный доступ

Натрий-йод симпортёр (NIS) - трансмембранный белок, участвующий в поглощении йодида в фолликулярных клетках щитовидной железы. Он играет критическую роль в метаболизме йода, широко используется в диагностике и лечении доброкачественных и злокачественных заболеваний щитовидной железы. В статье рассмотрены структура гена NIS, экспрессия натрий-йод симпортёра в тиреоидных и не тиреоидных тканях, в норме и опухолях, биологическая роль снижения экспрессии NIS в онкогенезе и метастазировании, а также участие в радиойодтерапии тиреоидных тканей.

Натрий-йод симпортёр, na+/i- симпортёр (nis), радиойодтерапия, рак щитовидной железы

Короткий адрес: https://sciup.org/14955565

IDR: 14955565

Список литературы Na+/I- симпортер (NIS): структура, функции, экспрессия в норме и опухолях

Семенов Д.Ю., Борискова М.Е., Фарафонова У.В., Грозов Р.В. Прогностическое значение экспрессии натрий-йодного симпортера для высокодифференцированного рака щитовидной железы. Клиническая и экспериментальная тиреоидология. 2015. Т.11. № 1. С. 50-58.
Ahn B.C. Sodium Iodide Symporter for Nuclear Molecular Imaging and Gene Therapy: From Bedside to Bench and Back. Theranostics. 2012. V. 2. No. 4. P. 392-402.
Altorjay A., Dohan O., Szilagyi A., et al. Expression of the Na+/I-symporter (NIS) is markedly decreased or absent in gastric cancer and intestinal metaplastic mucosa of Barrett esophagus. BMC Cancer. 2007. V. 7:5.
Arturi F., Russo D., Giuffrida D., et al. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas. Eur J Endocrinol. 2000. V. 143. No.5.P. 623-627.
Arturi F., Russo D., Schlumberger M., et al. Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab. 1998. V. 83. No. 7. P. 2493-2496.
Bastos A.U., Oler G., Nozima B.H., et al. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma. Eur J Endocrinol. 2015. V. 173. No. 4. P. 525-540.
Beyer S.J., Zhang X., Jimenez R.E., et al. Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer. BMC Res Notes. 2011. V. 11. No. 4. P. 397.
Bidart J.M., Lacroix L., Evain-Brion D., et al. Expression of Na+/I-symporter and Pendred syndrome genes in trophoblast cells. J Clin Endocrinol Metab. 2000. V. 85. No. 11. P. 4367-4372.
Boron W.F., Boulpaep E.L. Medical Physiology: A Cellular and Molecular Approach. W.B. Saunders. 2003.
Bosch EH, van Doorne H, de Vries S. The lactoperoxidase system: The influence of iodide and the chemical and antimicrobial stability over the period of about 18 months. J Appl Microbiol. 2000. V. 89. No. 2. P. 215-224.
Brown-Grant K. Extrathyroidal iodide concentrating mechanisms. Physiol Rev. 1961. V.41.No. 1. P. 189-213.
Bruno R., Giannasio P., Ronga G., et al. Sodium iodide symporter expression and radioiodine distribution in extrathyroidal tissues. J Endocrinol Invest. 2004. V. 27. No. 11. V. 1010-1014.
Burrow G.N., Fisher D.A., Larsen P.R. Maternal and fetal thyroid function. N Engl J Med. 1994. V. 331. No. 16. P. 1072-1078.
Cho J.Y., Leveille R., Kao R., et al. Hormonal regulation of radioiodide uptake activity and Na+/I-symporter expression in mammary glands. J Clin Endocrinol Metab. 2000. V. 85. No. 8. P. 2936-2943.
Choi Y.W., Kim H.J., Kim Y.H., et al. BRAF V600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1. Exp Mol Med. 2014. V. 46. P. e120.
Chung J.K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med Sep. 2002. V. 43. No. 9. P. 1188-1200.
Damle A.A., Narkar A.A., Badwe R.A. Radioiodide uptake and sodium iodide symporter expression in breast carcinoma. Indian J Exp Biol. 2011. V. 49. No. 6. P. 416-422.
Darrouzet Е., Lindentha., Marcellin D., et al. The sodium/iodide symporter: State of the art of its molecular characterization. Biochim Biophys Acta. 2014. V.1838. No. 1. Pt B. P. 244-253.
De la Vieja A., Ginter C.S., Carrasco N. Molecular analysis of a congenital iodide transport defect: G543E impairs maturation and trafficking of the Na+/I-symporter. Mol Endocrinol. 2005. V. 19. No. 11. P. 2847-2858.
De La Vieja A., Ginter C.S., Carrasco N. The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number. J Cell Sci. 2004. V. 117. (Pt. 5). P. 677-687.
De la Vieja A., Reed M.D., Ginter C.S., et al. Amino acid residues in transmembrane segment IX of the Na+/I-symporter play a role in its Na+ dependence and are critical for transport activity. J Biol Chem. 2007. V. 282. No. 35. P. 25290-25298.
Dohán O., Gavrielides M.V., Ginter C., et al. Na+/I-symporter activity requires a small and uncharged amino acid residue at position 395. Mol Endocrinol. 2002. V. 16. No. 8. P. 1893-1902.
Dohán O., De la Vieja A., Paroder V., et al. Review The sodium/iodide Symporter (NIS): characterization, regulation, and medical significance. Endocr Rev. 2003. V. 24. No. 1. P. 48-
Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003. V. 3. No. 1. P. 11-22.
Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006. V. 91. No. 8. P. 2892-2899.
Durante C., Puxeddu E., Ferretti E., et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007. V.92.No. 7. P. 2840-2843.
Eskandari S., Loo D.D., Dai G., et al. Thyroid Na+/I-symporter. Mechanism, stoichiometry, and specificity. J Biol Chem. 1997. V. 272. No. 43. P. 27230-27238.
Farnedi A., Eusebi L.H., Poli F., Foschini M.P. Immunohistochemical expression of the human sodium/iodide symporter distinguishes malignant from benign gastric lesions. Int J Surg Pathol. 2009. V. 17. No. 4. P. 327-334.
Filetti S. Sodium/iodide symporter: A key transport system in thyroid cancer cell metabolism. Eur J Endocrinol. 1999. V. 141. No. 5. P. 443-457.
Fragoso M.A., Fernandez V., Forteza R., et al. Transcellular thiocyanate transport by human airway epithelia. J Physiol. 2004. V. 561. (Pt. 1.) P. 183-194.
Huc-Brandt S., Marcellin D., Graslin F., et al. Characterisation of the purified human sodium/iodide symporter reveals that the protein is mainly present in a dimeric form and permits the detailed study of a native C-terminal fragment. Biochim Biophys Acta. 2010. V. 1808. No. 1. P. 65-77.
Josefsson M., Grunditz T., Ohlsson T., et al. Sodium/iodide-symporter: distribution in different mammals and role in entero-thyroid circulation of iodide. Acta Physiol Scand. 2002. V. 175. P. 129-137.
La Perle K.M., Kim D.C., Hall N.C., et al. Modulation of sodium/iodide symporter expression in the salivary gland. Thyroid. 2013. V. 23. No. 8. P. 1029-1036.
De La Vieja A., Dohan O., Levy O., Carrasco N. Molecular analysis of the sodium/iodide symporter: impact on thyroid and extrathyroid pathophysiology. Physiol Rev. 2000. V. 80. No. 3. P. 1083-1105.
Lacoste C., Hervé J., Bou Nader M., et al. Iodide transporter NIS regulates cancer cell motility and invasiveness by interacting with the Rho guanine nucleotide exchange factor LARG. Cancer Res. 2012. V. 72. No. 21. P.5505-5515.
Lazar V., Bidart J.M., Caillou B., et al. Expression of the Na+/I-symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab. 1999. V. 84. N.o 9. P. 3228-3324.
Li W., Nicola J.P., Amzel L.M., Carrasco N. Asn 441 plays a key role in folding and function of the Na+/I-symporter (NIS). FASEB J. 2013. V. 27. No. 8. P. 3229-3238.
Liang J.A., Chen C.P., Huang S.J., et al. A novel loss-of-function deletion in sodium/iodide symporter gene in follicular thyroid adenoma. Cancer Lett. 2005. V. 230. No. 1. P. 65-71.
Melo M., da Rocha A.G., Vinagre J., et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014. V. 99. No. 5. P. E754-E765.
Micali S., Bulotta S., Puppin C., et al. Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer. BMC Cancer. 2014. V.14. P. 303.
Miller J.K., Swanson E.W., Spalding G.E. Iodine absorption, excretion, recycling, and tissue distribution in the dairy cow. J Dairy Sci. 1975. V. 58. No. 10. P. 1578-1593.
Montanelli L., Agretti P., Marco G. Congenital hypoThyroidism and late-onset goiter: identification and characterization of a novel mutation in the sodium/iodide symporter of the proband and family members. Thyroid. 2009. V. 19. No. 12. P. 1419-1425.
Moon D.H., Lee S.J., Park K.Y., et al. Correlation between 99mTc-pertechnetate uptakes and expression of human sodium iodide symporter in breast tumor tissues. Nucl Med Biol. 2001. V. 28. No. 7. P. 829-834.
Morari E.C., Marcello M.A., Guilhen A.C., et al. Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clin Endocrinol (Oxf). 2011. V. 75. No. 2. P. 247-254.
Navarra M., Micali S., Lepore S.M., et al. Expression of the sodium/iodide symporter in human prostate adenocarcinoma. Urology. 2010. V. 75. No. 4. P. 773-778.
Nicola J.P., Basquin C., Portulano C., et al. The Na+/I-symporter mediates active iodide uptake in the intestine. Am J Physiol Cell Physiol. 2009. V. 296. No. 4. P. C654-662.
Oh H.J., Chung J.K., Kang J.H., et al. The relationship between expression of the sodium/iodide symporter gene and the status of hormonal receptors in human breast cancer tissue. Cancer Res Treat. 2005. V. 37. No. 4. P. 247-250.
Paroder V., Nicola J.P., Ginter C.S., Carrasco N. The iodide transport defect-causing mutation R124H: a delta-amino group at position 124 is critical for maturation and trafficking of the Na+/I-symporter (NIS). J Cell Sci. 2013. V. 126. (Pt 15). P. 3305-3313.
Pohlenz J., Rosenthal I.M., Weiss R.E., et al. Congenital hypothyroidism due to mutations in the sodium/iodide symporter: identification of a nonsense mutation producing a downstream cryptic 3′ splice site. J Clin Invest. 1998. V. 101. No. 5. P. 1028.
Portulano C., Paroder-Belenitsky M., Carrasco N. The Na +/I -Symporter (NIS): Mechanism and Medical Impact. 2014. Endocr Rev. V. 35. No. 1. P. 106-149.
Pryma D.A., Mandel S.J. Radioiodine therapy for thyroid cancer in the era of risk stratification and alternative targeted therapies. J Nucl Med. 2014. V. 55. No. 9. P. 1485-1491.
Ravera S., Reyna-Neyra A., Ferrandino G., et al. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. Annu Rev Physiol. 2017. V.79.P. 261-289.
Reed-Tsur M.D., De la Vieja A., Ginter C.S., et al. Molecular characterization of V59E NIS, a Na+/I-symporter (NIS) mutant that causes congenital I-transport defect (ITD). Endocrinology. 2008. V. 149. No. 6. P. 3077-084.
Renier C., Vogel H., Offor O., et al. Breast cancer brain metastases express the sodium iodide symporter. J Neurooncol. 2010. V. 96. No. 3. P. 331-336.
Renier C., Yao C., Goris M., et al. Endogenous NIS Expression in Triple-Negative Breast Cancers. Ann Surg Oncol. 2009. V. 16. No. 4. P. 962-968.
Ringel M.D., Anderson J., Souza S.L., et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer. Mod Pathol. 2001. V. 14. No. 4. P. 289-296.
Ronga G., Bruno R., Puxeddu E., et al. Radioiodine uptake in non-lactating mammary glands: evidence for a causative role of hyperprolactinemia. Thyroid. 2007. V. 17. No. 4. P. 363-366.
Ryan J., Curran C.E., Hennessy E., et al. The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. 2011. PLoS One. V. 6No. 1:e16023.
Saito T., Endo T., Kawaguchi A., et al. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest. 1998. V. 101. No.7. P. 1296-1300.
Semba R.D., Delange F. Iodine in human milk: perspectives for infant health. Nutr Rev. 2001. V. 59. No. 8. (Pt 1). P. 269-278.
Spitzweg C., Dietz A.B., O’Connor M.K., Bergert E.R., et al. In vivo sodium iodide symporter Gene Therapy of prostate cancer. Gene Ther. 2001. V. 8. No. 20. P. 1524-1531.
Spitzweg C., Morris J.C. Sodium Iodide Symporter (NIS) and Thyroid. Hormones (Athens). 2002. V. 1. No. 1. P. 22-34.
Stratford A.L., Boelaert K., Tannahill L.A., et al. Pituitary tumor transforming gene binding factor: a novel transforming gene in thyroid tumorigenesis. J Clin Endocrinol Metab. 2005. V. 90. No. 7. P. 4341-4349.
Tandon A., Shrivastava A., Kumar A., et al. Sodium iodide symporter, estrogen receptor, and progesterone receptor expression in carcinoma breast-an immunohistochemical analysis. Indian J Pathol Microbiol. 2011. V. 54. No. 4. P. 745-751.
Tavares C., Coelho M.J., Eloy C., et al. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. Endocr Connect. 2018. V. 7. No. 1. P. 78-90.
Tazebay U.H., Wapnir I.L., Levy O., et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med. 2000. V. 6. No. 8. P. 871-878.
Upadhyay G., Singh R., Agarwal G., et al. Functional expression of sodium iodide symporter (NIS) in human breast cancer tissue. Breast Cancer Res Treat. 2003. V. 77. No. 2. P. 157-165.
Vinagre J., Almeida A., Populo H., et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013. V. 4. P. 2185.
Wapnir I.L., Goris M., Yudd A., et al. The Na+/I-symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res. 2004. V. 10. No. 13. P. 4294-4302.
Wapnir I.L., van de Rijn M., Nowels K., et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab. 2003. V. 88. No. 4. P. 1880-1888.

Еще

Статья научная